Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Among authors: kitano s. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
Alteration of treatment choices and the visual prognosis for diabetic macular edema in the era of anti-VEGF drugs: Analysis of the STREAT-DME 2 study.
Shimura M, Hirano T, Tsuiki E, Takamura Y, Morizane Y, Akiyama K, Yamamoto K, Hikichi T, Koto T, Kinoshita T, Kusuhara S, Yoshida S, Sakamoto SI, Kimura K, Sugimoto M, Kida T, Mitamura Y, Takatsuna Y, Washio N, Osaka R, Ueda T, Minamoto A, Kogo J, Okamoto F, Enaida H, Sakanishi Y, Nagaoka T, Gomi F, Sasaki M, Terasaki H, Iwase T, Tatsumi T, Nishi K, Shinoda K, Ueda S, Ueda-Consolvo T, Nakashizuka H, Murata T, Kitano S, Sakamoto T; J-CREST STREAT-DME 2 Study Group. Shimura M, et al. Among authors: kitano s. Retina. 2024 Oct 15. doi: 10.1097/IAE.0000000000004301. Online ahead of print. Retina. 2024. PMID: 39423137
Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents.
Sugimoto M, Chujo S, Kato K, Shimura M, Kitano S, Kusuhara S, Terasaki H, Kondo M, Writing Committee Of Japan-Clinical Retina Study Group J-Crest. Sugimoto M, et al. Among authors: kitano s. J Clin Med. 2024 Dec 2;13(23):7336. doi: 10.3390/jcm13237336. J Clin Med. 2024. PMID: 39685795 Free PMC article.
FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor.
Maruyama S, Imamura Y, Toihata T, Haraguchi I, Takamatsu M, Yamashita M, Nakashima Y, Oki E, Taguchi K, Yamamoto M, Mine S, Okamura A, Kanamori J, Nunobe S, Sano T, Kitano S, Noda T, Watanabe M. Maruyama S, et al. Among authors: kitano s. Cancer Sci. 2025 Jan;116(1):178-191. doi: 10.1111/cas.16373. Epub 2024 Oct 23. Cancer Sci. 2025. PMID: 39440906 Free PMC article.
1,214 results